# Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations

> **NCT02432313** · PHASE1 · COMPLETED · sponsor: **Rock Creek Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Pharmacokinetics of Anatabine

## Interventions

- **DRUG:** Modified Release Formulation x (MRx)

## Key facts

- **NCT ID:** NCT02432313
- **Lead sponsor:** Rock Creek Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432313, "Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02432313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*